Previous close | 6.10 |
Open | 6.10 |
Bid | 0.00 |
Ask | 0.00 |
Strike | 20.00 |
Expiry date | 2024-06-21 |
Day's range | 6.10 - 6.10 |
Contract range | N/A |
Volume | |
Open interest | N/A |
On Monday, Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) released topline results from the Phase 3 PALISADE study of plozasiran in patients with genetically confirmed or clinically diagnosed familial chylomicronemia syndrome (FCS). FCS is a rare metabolic disease that prevents the body from digesting fats. Related: What Arrowhead Pharmaceutical’s Interim Data Reveals About A RNAi Therapeutic For Rare Cholesterol Disorder The study met the primary endpoint of lowering triglycerides and all key sec
PASADENA, Calif., June 03, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results from the pivotal Phase 3 PALISADE study of investigational plozasiran in patients with genetically confirmed or clinically diagnosed familial chylomicronemia syndrome (FCS), a severe genetic disease with significant unmet need and no FDA approved therapies. PALISADE successfully met the primary endpoint of lowering triglycerides and met all key secondary endpoints, including reducing t
PASADENA, Calif., May 31, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: